Resistance to Immunotherapeutic Antibodies in Cancer Strategies to Overcome Resistance /

The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Bonavida, Benjamin (Επιμελητής έκδοσης)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: New York, NY : Springer New York : Imprint: Springer, 2013.
Σειρά:Resistance to Targeted Anti-Cancer Therapeutics, 2
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
Πίνακας περιεχομένων:
  • Preface
  • Introduction and generation of chimeric and humanized mAbs
  • mAbs targeted against cancer cells and antibodies targeted against the tumor microenvironment
  • Antibodies directed against different major cancers: Effects when used  alone or in combination with drugs
  • Mechanisms of antibodies-mediated responses, in vitro and in vivo
  • Molecular Pathways
  • Molecular Signatures
  • Identification of resistance targets for intervention
  • Various chemicals that can sensitize resistant tumor cells
  • Other mAbs
  • Proteasome inhibitors
  • Divalent mAbs
  • Antibodies coupled to chemical inhibitors
  • Antibodies coupled to cytokines
  • Nanoparticles with mAbs
  • Index.